{"DataElement":{"publicId":"7150290","version":"1","preferredName":"Systemic Mastocytosis Disease or Disorder Classification Type","preferredDefinition":"A description of the systemic mastocytosis disease or disorder classification.","longName":"7150237v1.0:7150287v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7150237","version":"1","preferredName":"Systemic Mastocytosis Disease or Disorder Classification","preferredDefinition":"A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"7150235v1.0:2321361v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7150235","version":"1","preferredName":"Systemic Mastocytosis Disease or Disorder","preferredDefinition":"A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"C9235:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Mastocytosis","conceptCode":"C9235","definition":"Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D227CB5-8729-7538-E053-F662850AFBEC","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D227CB5-8737-7538-E053-F662850AFBEC","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"MALUMK","dateModified":"2020-12-03","changeDescription":"Released. 12/03/2020 KMM; Released. 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7150287","version":"1","preferredName":"Systemic Mastocytosis Classification Type","preferredDefinition":"A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003_A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Something distinguishable as an identifiable class based on common qualities.","longName":"7150287v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Mast cell leukemia (MCL)","valueDescription":"Mast Cell Leukemia","ValueMeaning":{"publicId":"2590857","version":"1","preferredName":"Mast Cell Leukemia","longName":"2590857","preferredDefinition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Leukemia","conceptCode":"C3169","definition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B55A-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D229F26-8E4D-5BE4-E053-F662850A53F3","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Aggressive systemic mastocytosis (ASM)","valueDescription":"Aggressive Systemic Mastocytosis","ValueMeaning":{"publicId":"2836825","version":"1","preferredName":"Aggressive Systemic Mastocytosis","longName":"2836825","preferredDefinition":"An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive Systemic Mastocytosis","conceptCode":"C9285","definition":"An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-073E-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D229F26-8E61-5BE4-E053-F662850A53F3","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)","valueDescription":"Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease","ValueMeaning":{"publicId":"2838860","version":"1","preferredName":"Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease","longName":"2838860","preferredDefinition":"A disorder characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells and the presence of a clonal non-mast cell hematologic neoplasm (e.g., myelodysplastic syndrome, chronic myeloproliferative disorder, acute myeloid leukemia, and lymphoma).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Mastocytosis with an Associated Myeloid Neoplasm","conceptCode":"C9284","definition":"A disorder characterized by systemic infiltration of internal organs by aggregates of clonal mast cells and the presence of a clonal non-mast cell myeloid neoplasm (e.g., myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A9A-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D229F26-8E76-5BE4-E053-F662850A53F3","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Smoldering systemic mastocytosis (SSM)","valueDescription":"Smoldering Systemic Mastocytosis","ValueMeaning":{"publicId":"7150289","version":"1","preferredName":"Smoldering Systemic Mastocytosis","longName":"7150289","preferredDefinition":"Slowly progressive systemic mastocytosis with uncertain prognosis. It is characterized by organomegaly and absence of aggressive disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Smoldering Systemic Mastocytosis","conceptCode":"C115460","definition":"Slowly progressive systemic mastocytosis with uncertain prognosis. It is characterized by organomegaly and absence of aggressive disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D229F26-8E84-5BE4-E053-F662850A53F3","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D229F26-8E9D-5BE4-E053-F662850A53F3","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Indolent systemic mastocytosis (ISM)","valueDescription":"Indolent Systemic Mastocytosis","ValueMeaning":{"publicId":"2838579","version":"1","preferredName":"Indolent Systemic Mastocytosis","longName":"2838579","preferredDefinition":"An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indolent Systemic Mastocytosis","conceptCode":"C9286","definition":"An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-58B2-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D229F26-8EB1-5BE4-E053-F662850A53F3","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","deletedIndicator":"No"},{"value":"Bone marrow mastocytosis","valueDescription":null,"ValueMeaning":{"publicId":"14679056","version":"1","preferredName":"Bone Marrow Mastocytosis","longName":"14679056v1.00","preferredDefinition":"A variant of indolent systemic mastocytosis that affects predominantly older males. It is characterized by a limited degree of bone marrow infiltration by clonal mast cells and an absence of skin involvement. The serum tryptase levels are normal or slightly elevated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Marrow Mastocytosis","conceptCode":"C198573","definition":"A variant of indolent systemic mastocytosis that affects predominantly older males. It is characterized by a limited degree of bone marrow infiltration by clonal mast cells and an absence of skin involvement. The serum tryptase levels are normal or slightly elevated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F17695B-E796-41F3-E063-731AD00A793F","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F17695B-E797-41F3-E063-731AD00A793F","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7150286","version":"1","preferredName":"Systemic Mastocytosis Classification Type","preferredDefinition":"A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Something distinguishable as an identifiable class based on common qualities.","longName":"C9235:C25161:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Mastocytosis","conceptCode":"C9235","definition":"Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D229F26-8E1D-5BE4-E053-F662850A53F3","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D229F26-8E2E-5BE4-E053-F662850A53F3","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":".Released 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_MPN_systemic_mast_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the systemic mastocy","type":"Preferred Question Text","description":"What was the systemic mastocytosis disease or disorder classification?","url":null,"context":"NHLBI"},{"name":"Specify systemic mastocytosis","type":"Alternate Question Text","description":"Specify systemic mastocytosis","url":null,"context":"NHLBI"},{"name":"Specify systemic mastocytosis","type":"Application Standard Question Text","description":"Specify systemic mastocytosis","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D22BB9B-4DBC-6620-E053-F662850AC088","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"MALUMK","dateModified":"2020-11-11","changeDescription":"Released. 11/11/2020 KMM; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}